Alvimopan Patent Expiration
Alvimopan is Used for accelerating gastrointestinal recovery following bowel resection surgeries. It was first introduced by Cubist Pharmaceuticals Inc
Alvimopan Patents
Given below is the list of patents protecting Alvimopan, along with the drug name that holds that patent and the company name owning that drug.
Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
---|---|---|---|---|
Entereg | US8112290 | Methods for delivering a drug to a hospital patient for short-term use while minimizing long-term use of the drug | Jul 31, 2030 | Cubist Pharms |
Entereg | US8946262 | Methods of preventing and treating gastrointestinal dysfunction | Feb 12, 2030 | Cubist Pharms |
Entereg | US8645160 | Methods for delivering a drug to a hospital patient for short-term use while minimizing long-term use of the drug | Jun 18, 2029 | Cubist Pharms |
Entereg | US6469030 | Methods for the treatment and prevention of ileus |
Nov 29, 2020
(Expired) | Cubist Pharms |
Entereg | US5250542 | Peripherally selective piperidine carboxylate opioid antagonists |
Mar 29, 2016
(Expired) | Cubist Pharms |
Entereg | US5434171 | Preparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and intermediates |
Dec 08, 2013
(Expired) | Cubist Pharms |
Alvimopan's Family Patents

Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List